India is poised to reject Shanghai Fosun Pharmaceutical Group Co.’s proposed $1.3 billion takeover of an Indian drugmaker, according to people familiar with the matter, scuppering the biggest-ever Chinese acquisition in the country. The Cabinet Committee on Economic Affairs, which is chaired by Prime Minister Narendra Modi, has decided to block the Chinese firm’s purchase of an 86 percent stake in Gland Pharma Ltd., according to the people. The companies haven’t been formally notified yet of the move, the people said, asking not to be identified because the information is private.
Tensions between China and India have escalated amid a renewed spat over territory in a remote area of the Himalayas, one of the most serious flareups between the two Asian giants since a border war in 1962. A collapse of the acquisition would be a setback for Fosun Pharma, which had sought Gland Pharma’s stable of generic injectable medicines and facilities approved to manufacture products for sale in the U.S. Read More…
Credit By: Financial Express
Latest posts by Financial Express (see all)
- Bajaj Auto aims to debut EV portfolio by 2020 - July 21, 2018
- Bhushan Power: Little Liberty For Lenders To Select Winning Bidder - July 21, 2018
- CAG On Railways – ‘GE Unit Not In Sync, Rethink Flexi-fares’ - July 21, 2018